Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397302 | 1.00 | ALDH1A1 (0.37) | ALDH1A1HTR1AKMT2AMGAMSI | |
| SCHEMBL6396632 | 1.00 | ALDH1A1 (0.37) | ALDH1A1HTR1AKMT2AMGAMSI | |
| SCHEMBL17291825 | 0.84 | HTR1A (0.39) | ALDH1A1HTR1AKMT2A | |
| SCHEMBL1848674 | 0.75 | TSHR (0.36) | ALDH1A1HTR1AKMT2A | |
| SCHEMBL6390289 | 0.75 | ANPEP (0.42) | ALDH1A1HTR1AKMT2A | |
| SCHEMBL21316453 | 0.75 | ANPEP (0.42) | ALDH1A1HTR1AKMT2A | |
| SCHEMBL1848675 | 0.75 | TSHR (0.36) | ALDH1A1HTR1AKMT2A | |
| SCHEMBL6390292 | 0.75 | ANPEP (0.42) | ALDH1A1HTR1AKMT2A | |
| SCHEMBL19206550 | 0.73 | KMT2A (0.43) | ALDH1A1KMT2A | |
| SCHEMBL8442337 | 0.71 | FUCA1 (0.42) | HTR1AMGAMSISLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939986-B2 | Process for preparing 1,2-diamino compounds | HOFFMANN-LA ROCHE INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1059283-B1 | Process for preparing neuraminidase inhibitor ro-64-0796 | HOFFMANN LA ROCHE (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6437171-B1 | AZIDE-FREE; PREPARING 2-AMINOALCOHOLS FROM 1,2-EPOXIDES AND AN AMINE; PROTECTING THE FREE AMINO GROUP, HYDROXY LEAVING GROUP, DEPROTECTING, REACTING WITH AN AMINE, ACYLATING, DEPROTECTING | HOFFMAN-LA ROCHE INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020095040-A1 | Process for preparing 1,2-diamino compounds | KARPF MARTIN (CH) | 2002-07-18 | — | — | US | disclosed |
| EP-1059283-A1 | Process for preparing neuraminidase inhibitor ro-64-0796 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095040-A1 | Process for preparing 1,2-diamino compounds | AOC1, UGT1A1, THPO | ALDH1A1 48/4885HTR1A 411/4885KMT2A 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.